Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Endocrinology
•
Bone and Calcium Disorders
•
Primary Care
How long should a patient be treated with a bisphosphonate after a course of an anabolic medication has been completed?
Related Questions
As part of work up for hyperparathyroidism, what form of calcium replacement(dietary or supplements) would you recommend in a patient with a history of gastric bypass and multiple calcium containing kidney stones?
When cinacalcet is used to treat hypercalcemia in primary hyperparathyroidism, does it also normalize low serum phosphorus levels?
Do you recommend a particular antiresorptive/anabolic agent for patients who are at high risk for fractures but have high risk of osteonecrosis of the jaw?
How do you determine osteoporosis treatment response when patients have discrepant DEXA scan results during monitoring (eg improved BMD of the hip and spine but worsening BMD of the femoral neck)?
During treatment of severe osteoporosis, with PTH analogs (abaloparatide or) would rise in alkaline phosphatase level > 200 (in setting of normal GGT) warrant discontinuation of medication?
How reliable is the FRAX score for assessing risk of osteoporotic fractures?
When discontinuing Denosumab after more than 2-3 years of therapy, when do you recommend giving the first dose of zoledronic acid?
Do you recommend adjusting the duration of a drug holiday based on the specific bisphosphonate used when treating osteoporosis?
Is there any role for 25-OH Vitamin D testing in patients older than 75 years old in the general population?
Do you recommend the use of Denosumab for osteoporosis management in patients receiving IVIG therapy?
